{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:24:27Z","timestamp":1775575467673,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:00:00Z","timestamp":1699747200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014384","name":"Amarin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Metabolic syndrome (MetSyn) is associated with high risk of cardiovascular (CV) events, irrespective of statin therapy. In the overall REDUCE-IT study of statin-treated patients, icosapent ethyl (IPE) reduced the risk of the primary composite endpoint (CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or unstable angina requiring hospitalization) and the key secondary composite endpoint (CV death, non-fatal myocardial infarction, or non-fatal stroke).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>REDUCE-IT was an international, double-blind trial that randomized 8179 high CV risk statin-treated patients with controlled LDL cholesterol and elevated triglycerides to IPE 4 g\/day or placebo. The current study evaluated the pre-specified patient subgroup with a history of MetSyn, but without diabetes at baseline. Among patients with MetSyn but without diabetes at baseline (n = 2866), the majority (99.8%) of this subgroup was secondary prevention patients. Icosapent ethyl use was associated with a 29% relative risk reduction for the first occurrence of the primary composite endpoint [hazard ratio: 0.71; 95% confidence interval (CI): 0.59\u20130.84; P &amp;lt; 0.0001, absolute risk reduction (ARR) = 5.9%; number needed to treat = 17] and a 41% reduction in total (first plus subsequent) events [rate ratio: 0.59; (95% CI: 0.48\u20130.72); P &amp;lt; 0.0001] compared with placebo. The risk for the key secondary composite endpoint was reduced by 20% (P = 0.05) and a 27% reduction in fatal\/non-fatal MI (P = 0.03), 47% reduction in urgent\/emergent revascularization (P &amp;lt; 0.0001), and 58% reduction in hospitalization for unstable angina (P &amp;lt; 0.0001). Non-statistically significant reductions were observed in cardiac arrest (44%) and sudden cardiac death (34%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In statin-treated patients with a history of MetSyn, IPE significantly reduced the risk of first and total CV events in REDUCE-IT. The large relative and ARRs observed supports IPE as a potential therapeutic consideration for patients with MetSyn at high CV risk.<\/jats:p>\n                  <jats:p>Registration REDUCE-IT ClinicalTrials.gov number: NCT01492361<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjopen\/oead114","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T11:04:08Z","timestamp":1699873448000},"source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1679-2095","authenticated-orcid":false,"given":"Michael","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Medicine, Corporal Michael J. Crescenz Veterans Affairs Medical Center and Hospital of the University of Pennsylvania , 3900 Woodland Avenue, Philadelphia, PA 19104-4551 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliot A","family":"Brinton","sequence":"additional","affiliation":[{"name":"Utah Lipid Center , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry A","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, FACT (French Alliance for Cardiovascular Trials), Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Bichat, INSERM Unit\u00e9 1148 , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando Lira","family":"Pineda","sequence":"additional","affiliation":[{"name":"Amarin Pharma, Inc. (Amarin) , Bridgewater, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven B","family":"Ketchum","sequence":"additional","affiliation":[{"name":"Amarin Pharma, Inc. (Amarin) , Bridgewater, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Ralph T","family":"Doyle","sequence":"additional","affiliation":[{"name":"Amarin Pharma, Inc. (Amarin) , Bridgewater, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , Montreal , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Texas Heart Institute , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,12]]},"reference":[{"key":"2024030500474254800_oead114-B1","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1001\/jama.2020.4501","article-title":"Trends in the prevalence of metabolic syndrome in the United States, 2011\u20132016","volume":"323","author":"Hirode","year":"2020","journal-title":"JAMA"},{"key":"2024030500474254800_oead114-B2","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2024030500474254800_oead114-B3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2024030500474254800_oead114-B4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2023.03.024","article-title":"Metabolic syndrome and risk of incident heart failure in non-diabetic patients with established cardiovascular disease","volume":"379","author":"Burger","year":"2023","journal-title":"Int J Cardiol"},{"key":"2024030500474254800_oead114-B5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3390\/jcm12041614","article-title":"The effect of metabolic syndrome and its individual components on renal function: a meta-analysis","volume":"12","author":"Li","year":"2023","journal-title":"J Clin Med"},{"key":"2024030500474254800_oead114-B6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s11739-023-03226-7","article-title":"Diet and metabolic syndrome: a narrative review","volume":"18","author":"Angelico","year":"2023","journal-title":"Intern Emerg Med"},{"key":"2024030500474254800_oead114-B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024030500474254800_oead114-B8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"2024030500474254800_oead114-B9","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024030500474254800_oead114-B10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-020-01166-6","article-title":"Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort","volume":"19","author":"Guembe","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2024030500474254800_oead114-B11","doi-asserted-by":"crossref","first-page":"e3502","DOI":"10.1002\/dmrr.3502","article-title":"Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors","volume":"38","author":"Silveira Rossi","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"key":"2024030500474254800_oead114-B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00281-017-0666-5","article-title":"Hemostasis, endothelial stress, inflammation, and the metabolic syndrome","volume":"40","author":"Grandl","year":"2018","journal-title":"Semin Immunopathol"},{"key":"2024030500474254800_oead114-B13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024030500474254800_oead114-B14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"2024030500474254800_oead114-B15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacl.2017.06.017","article-title":"Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: a post hoc analysis of the AIM-HIGH trial","volume":"11","author":"Lyubarova","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2024030500474254800_oead114-B16","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2024030500474254800_oead114-B17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2024030500474254800_oead114-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/obr.12229","article-title":"Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies","volume":"16","author":"O\u2019Neill","year":"2015","journal-title":"Obes Rev"},{"key":"2024030500474254800_oead114-B19","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"2024030500474254800_oead114-B20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3109\/09637486.2015.1025716","article-title":"Effect of fruits and vegetables on metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"66","author":"Shin","year":"2015","journal-title":"Int J Food Sci Nutr"},{"key":"2024030500474254800_oead114-B21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2047487314562741","article-title":"The effectiveness of yoga in modifying risk factors for cardiovascular disease and metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Chu","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2024030500474254800_oead114-B22","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jacl.2016.04.011","article-title":"Poly is more effective than mono\u2014unsaturated fat for dietary management in the metabolic syndrome: the MUFFIN study","volume":"10","author":"Miller","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2024030500474254800_oead114-B23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"2024030500474254800_oead114-B24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"2024030500474254800_oead114-B25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S2213-8587(22)00043-2","article-title":"Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"10","author":"Ostadal","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024030500474254800_oead114-B26","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024030500474254800_oead114-B27","doi-asserted-by":"crossref","first-page":"e022937","DOI":"10.1161\/JAHA.121.022937","article-title":"Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI","volume":"11","author":"Peterson","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024030500474254800_oead114-B28","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"2024030500474254800_oead114-B29","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"2024030500474254800_oead114-B30","doi-asserted-by":"crossref","first-page":"e024999","DOI":"10.1161\/JAHA.121.024999","article-title":"Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT","volume":"11","author":"Selvaraj","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024030500474254800_oead114-B31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ehjcvp\/pvac045","article-title":"Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking","volume":"9","author":"Miller","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oead114\/53271401\/oead114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/3\/6\/oead114\/56832082\/oead114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/3\/6\/oead114\/56832082\/oead114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:48:00Z","timestamp":1709599680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oead114\/7406682"}},"subtitle":[],"editor":[{"given":"Magnus","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oead114","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11]]},"article-number":"oead114"}}